This document discusses predictive neurostimulation (PNS), a new technology for treating intractable seizures. PNS uses a device implanted in the brain to identify seizure-related neurological activity 4-12 minutes before onset and suppresses the seizures without any discomfort. Initial data from 10 patients showed 86% accuracy in detecting seizures and the system stopped 100% of detected seizures. PNS offers clinicians a new treatment option for the over 1 million epilepsy patients who do not benefit from drugs, with fewer side effects than existing options like VNS. The US epilepsy market represents a $20 billion opportunity.